Related Experiment Videos
[Revascularization versus transplantation in patients with limited ejection fraction]
I Muñoz Carvajal1, M Concha Ruiz
1Servicio de Cirugía Cardiovascular, Hospital Reina Sofía, Córdoba.
Revista Espanola De Cardiologia
|August 26, 1998
Summary
Ischemic ventricular dysfunction, previously a contraindication for surgery, can now be treated with revascularization. Assessing myocardial viability is key to improving outcomes for patients with severe heart dysfunction due to coronary disease.
Area of Science:
- Cardiology
- Cardiovascular Surgery
- Physiology
Context:
- Ventricular dysfunction from ischemia is common in coronary artery disease and heart failure.
- Therapeutic approaches differ based on myocardial necrosis versus circulatory deficiency, influenced by ischemia duration and reperfusion.
- Historically, severe dysfunction was a contraindication for revascularization, with patients referred for heart transplantation or medical management.
Purpose:
- To analyze the physiopathology of ventricular dysfunction.
- To review current methods for assessing myocardial viability.
- To discuss indications and outcomes of ventricular revascularization in patients with severe ventricular dysfunction.
Summary:
- Myocardial viability assessment is now central to deciding on revascularization for ischemic ventricular dysfunction.
- Revascularization is increasingly performed in patients with severe heart failure due to limited transplant donors and suboptimal medical treatment.
- Accurate viability assessment allows prediction of clinical and functional improvement in patients with severe cardiac dysfunction.
Impact:
- Revascularization offers a viable alternative to heart transplantation for selected patients with severe ventricular dysfunction.
- Improved diagnostic methods enhance the ability to identify patients who will benefit from revascularization.
- This approach can lead to significant clinical and functional improvements in patients with coronary disease and impaired cardiac function.